Els O. Witteveen - Concepedia

Author

Els O. Witteveen

Also Known As

E O Witteveen, E Witteveen, E. O. Witteveen, E. WITTEVEEN, E. Witteveen, Els O Witteveen, Els O. Witteveen, Els Witteveen, Emma Witteveen, Martine van Grotel

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

University Medical Center Utrecht The Netherlands Cancer Institute Utrecht University Slotervaartziekenhuis Radboud University Nijmegen

About

Els O. Witteveen is an author at University Medical Center Utrecht specializing in oncology, cancer research, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	42
2	Pharmacology	2	2	42
3	Cell Biology	1	1	30
4	Cancer Cell Biology	1	1	30
5	Cancer Therapeutics	1	1	12

Els O. Witteveen

Publications

960

Citations

H-Index

Page 1

	Year	Citations
A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients I. E. L. M. Kuppens, Els O. Witteveen, Roxanne C. Jewell, Clinical Cancer Research	2007	174
Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel Tessa M. Bosch, Alwin D. R. Huitema, Valerie D. Doodeman, Clinical Cancer Research	2006	125
Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study Kristel Van Calsteren, René Verbesselt, Nelleke Ottevanger, Acta Obstetricia Et Gynecologica Scandinavica	2010	120
Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid Tumors Laurens V. Beerepoot, Sandra A. Radema, Els O. Witteveen, Journal of Clinical Oncology	2006	114
Late Release of Circulating Endothelial Cells and Endothelial Progenitor Cells after Chemotherapy Predicts Response and Survival in Cancer Patients Jeanine M.L. Roodhart, Marlies H.G. Langenberg, Joost S.P. Vermaat, Neoplasia	2010	79
Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Laurens V. Beerepoot, Els O. Witteveen, Gerard Groenewegen, PubMed	2003	64
Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy Tineke Vandenbroucke, Magali Verheecke, Mathilde van Gerwen, European Journal of Cancer	2020	59
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer Jeany M. Rademaker-Lakhai, Laurens V. Beerepoot, Niven Mehra, Clinical Cancer Research	2007	52
Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors Stephan A. Veltkamp, Els O. Witteveen, Angela Capriati, Clinical Cancer Research	2008	42
Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer M J Verhaar-Langereis, Abdullah Karakuş, M. Van Eijkeren, International Journal of Gynecological Cancer	2006	30

Page 1